Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy rating and $1,281 price target for Eli Lilly & Company (NYSE:LLY) shares on April 17, following encouraging Phase 3 trial outcomes for Foundayo in type 2 diabetes. Eli Lilly & Company (NYSE:LLY) reported the results of ACHIEVE-4, a 52-week non-inferiority trial that evaluated Foundayo in over 2,700 type 2 diabetes patients from 15 countries. The trial met its primary goal, showing no inferiority to insulin glargine in terms of significant cardiovascular complications.
Compared to insulin glargine, Foundayo had a 57% decreased risk of all-cause death. According to Eli Lilly & Company (NYSE:LLY), the Phase 3 program, which now consists of seven Phase 3 studies and over 11,000 patients, has not yet shown any liver safety indications for the medication.
By the end of the second quarter of 2026, the company intends to submit Foundayo for type 2 diabetes approval in the US. In order to assess an unexpected significant risk for major adverse cardiovascular events and drug-associated liver disease, the FDA has already asked for more post-marketing research.
Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Leave a Reply